Howard Marks Diagnosed with Throat Cancer
Oaktree Capital Group co-founder Howard Marks has been diagnosed with throat cancer, according to a report from the Financial Times. The billionaire investor, who is one of the most respected names in the finance industry, is set to undergo treatment for the disease.
Marks, who is 74 years old, is the co-chairman of the Los Angeles-based investment firm. He is known for his best-selling books on investing, including The Most Important Thing and The Most Important Thing Illuminated.
Oaktree Capital Group
Oaktree Capital Group is one of the world’s largest alternative investment firms. It was founded in 1995 by Marks and five other partners. The firm has more than $120 billion in assets under management and is one of the most successful investment firms in the world.
Marks has been a key figure in the firm’s success. He is known for his ability to spot opportunities in distressed debt and other investments. He is also known for his contrarian approach to investing, which has helped the firm to generate strong returns for its investors.
Throat Cancer Diagnosis
Marks was diagnosed with throat cancer in April of this year. He is set to undergo treatment for the disease, but the details of the treatment have not been disclosed.
The news of Marks’ diagnosis has sent shockwaves through the financial world. He is one of the most respected figures in the industry and his diagnosis has been met with an outpouring of support from his colleagues and peers.
Impact on Oaktree Capital Group
Marks’ diagnosis has raised questions about the future of Oaktree Capital Group. The firm has not yet commented on the situation, but it is likely that Marks’ treatment will have an impact on the firm’s operations.
Marks is the co-chairman of the firm and is heavily involved in its day-to-day operations. It is unclear how his treatment will affect the firm’s operations, but it is likely that his absence will be felt.
Support for Howard Marks
Marks’ diagnosis has been met with an outpouring of support from his colleagues and peers. Many of the firm’s investors have expressed their support for Marks and their hope for a speedy recovery.
The news of Marks’ diagnosis has also sparked a renewed appreciation for his work and his contributions to the finance industry. He is widely respected for his ability to spot opportunities in distressed debt and other investments.
Conclusion
Oaktree Capital Group co-founder Howard Marks has been diagnosed with throat cancer. He is set to undergo treatment for the disease, but the details of the treatment have not been disclosed. The news of Marks’ diagnosis has sent shockwaves through the financial world and has been met with an outpouring of support from his colleagues and peers. It is unclear how his treatment will affect the firm’s operations, but it is likely that his absence will be felt.